We proposed research to devise and improve pharmacokinetic (PK) and pharmacodynamic (PD) data-analyiss methods, with special emphasis on the latter. These mehtods provide parameter estimates, confidence regions for parameters, and tests of hypotheses about parameter or the goodness of fit of alternative models. Given the realities of clinicla pharmacologicla data concerning drug concentrations and drug actions, the data analysis methods we devise and test must be able to analyze data with varying characteristics: (1) Experimental-type data (many observations per individual; few individuals) or observational-type data arising from patient care or as add-on data to ongoing clinical trials (few observations per individual; many individuals). (2) Data viewed as arising from an individual or as arising from a population. The distinction is that from the former viewpoint, the focus is the PK/PD behavior of the paticular individual, while from the latter viewpoint, the focus is population mean PK/PD behavior, inter-individual variability and residual intra-individual an measurement error variability. (3) Continuous-valued (cardinal) response, such as drug concentrations, or blood pressure or categories (often ordinal) responses, such as """"""""response"""""""" vs """"""""no response"""""""". (4) Univariate responses, such as plasma concentrations, or multivariate responses, such ase concentrations in both plasma and urine, plus pharmocologic effects. This category also logically includes mulitivariate responses, some elements of which ar continuous-valued and some categorical. For our research to have meaning, it must be available for use by others. We have implemented our methods as exportable computer programs, and have distributed them to users around the world. Furter such implementation is planned in this renewal. Although we do not request direct grant support to do so, we plan also to apply our methods to real-world data. This supplies needed insight and impetus for our research.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM026676-12
Application #
3274073
Study Section
Pharmacology A Study Section (PHRA)
Project Start
1979-09-01
Project End
1992-08-31
Budget Start
1990-09-01
Budget End
1991-08-31
Support Year
12
Fiscal Year
1990
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Frymoyer, Adam; Meng, Lina; Bonifacio, Sonia L et al. (2013) Gentamicin pharmacokinetics and dosing in neonates with hypoxic ischemic encephalopathy receiving hypothermia. Pharmacotherapy 33:718-26
Frymoyer, A; Lee, S; Bonifacio, S L et al. (2013) Every 36-h gentamicin dosing in neonates with hypoxic-ischemic encephalopathy receiving hypothermia. J Perinatol 33:778-82
Frame, Bill; Beal, Stuart L; Miller, Raymond et al. (2007) Mixed effects modeling of weight change associated with placebo and pregabalin administration. J Pharmacokinet Pharmacodyn 34:753-70
Levi, Micha; Dempsey, Delia A; Benowitz, Neal L et al. (2007) Population pharmacokinetics of nicotine and its metabolites I. Model development. J Pharmacokinet Pharmacodyn 34:5-21
Levi, Micha; Dempsey, Delia A; Benowitz, Neal L et al. (2007) Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application. J Pharmacokinet Pharmacodyn 34:23-34
Beal, Stuart L (2005) Conditioning on certain random events associated with statistical variability in PK/PD. J Pharmacokinet Pharmacodyn 32:213-43
Zhang, Liping; Sheiner, Lewis B (2005) Analyzing multi-response data using forcing functions. J Pharmacokinet Pharmacodyn 32:283-305
Kenna, Leslie A; Sheiner, Lewis B (2004) Estimating treatment effect in the presence of non-compliance measured with error: precision and robustness of data analysis methods. Stat Med 23:3561-80
Soy, Dolors; Beal, Stuart L; Sheiner, Lewis B (2004) Population one-compartment pharmacokinetic analysis with missing dosage data. Clin Pharmacol Ther 76:441-51
Zhang, Liping; Beal, Stuart L; Sheinerz, Lewis B (2003) Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods. J Pharmacokinet Pharmacodyn 30:405-16

Showing the most recent 10 out of 55 publications